Peter Triporo
Acute Care · Dallas, TXNPI 1184050544
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,622 of the $15,191 with a category attached, or 83.1%. 34 manufacturers reported payments, led by Viiv Healthcare Company at 47.1% of the total. Among acute care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 594 payments — averaging $25.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$7K
- Gilead$2K
- Merck$1K
- AbbVie$722
- Johnson & Johnson$552
- EMD Serono, Inc.$515
- plus $3K from 28 others
What the payments were for
- Consulting fees$2,40016%
- Food & beverage$12,62283%
- Education$1681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 207 | $7,149 |
| Gilead | 100 | $2,302 |
| Merck | 55 | $1,223 |
| AbbVie(2 entities) | 43 | $722 |
| Johnson & Johnson(2 entities) | 29 | $552 |
| EMD Serono, Inc. | 29 | $515 |
| Theratechnologies Inc. | 15 | $313 |
| Napo Pharmaceuticals Inc | 13 | $308 |
| Novo Nordisk | 18 | $301 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $227 |
| Antares Pharma, Inc. | 11 | $165 |
| Otsuka America Pharmaceutical, Inc. | 9 | $163 |
| Acacia Pharma Inc | 1 | $135 |
| Janssen Products, LP | 2 | $135 |
| Pfizer | 6 | $128 |
| Lilly USA, LLC | 7 | $112 |
| GSK | 5 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $78 |
| Axsome Therapeutics, Inc. | 3 | $73 |
| Supernus Pharmaceuticals, Inc. | 3 | $71 |
| AstraZeneca | 4 | $61 |
| Amarin Pharma, Inc. | 3 | $51 |
| Abbott | 2 | $43 |
| Alkermes, Inc. | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Verity Pharmaceuticals Inc. | 2 | $34 |
| Amgen | 1 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Tolmar, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| Orexo US, Inc. | 1 | $14 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
| Halozyme Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,191 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 44 | $225,967 |
| DovatoDolutegravir Sodium/Lamivudine | 18 | $57,482 |
| TivicayDolutegravir Sodium | 23 | $51,073 |
| DescovyEmtricitabine/Tenofov Alafenam | 19 | $41,492 |
| OzempicSemaglutide | 31 | $29,245 |
| PrezcobixDarunavir/Cobicistat | 11 | $26,630 |
| PifeltroDoravirine | 13 | $22,519 |
| Abacavir-LamivudineAbacavir Sulfate/Lamivudine | 13 | $13,598 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $2,432 |
| Atorvastatin Calcium | 71 | $623 |
| Duloxetine Hcl | 37 | $488 |
| Gabapentin | 23 | $270 |
| Tamsulosin Hcl | 26 | $232 |
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 15 | $212 |
| Losartan Potassium | 17 | $181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Janssen Products, LPSymtuza | $135 | $225,96744 claims |
| Viiv Healthcare CompanyDovato, Tivicay | $7,149 | $108,55541 claims |
| GileadDescovy | $2,302 | $41,49219 claims |
| Novo NordiskOzempic | $301 | $29,24531 claims |
| Johnson & JohnsonPrezcobix | $552 | $26,63011 claims |
| MerckPifeltro | $1,223 | $22,51913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,323 acute care providers in Texas.
Other acute care in Dallas
- Jennifer PilotteDallas$232K
- Amanda BradleyDallas$85K
- Martha LibertyDallas$28K
- Rachael SchneiderDallas$20K
- Mario PadillaDallas$13K
- Toni SmithDallas$10K
- Christie MorrisonSan Antonio$225K
- Laura WilsonEl Paso$32K
- Kim HuynhCypress$29K
- Afton DickersonHouston$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.